Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, announced a Series B financing of $80 million led by Northpond Ventures. Synthesis Capital also participated in the round. Existing investors Cultivian Sandbox Ventures, The Production Board, Craft Ventures, E14 Fund, Box Group, Verily Life Sciences, and Section 32 also contributed. Andrew Lee, Ph.D., of Northpond Ventures will join Culture’s Board of Directors.

"Recently there’s been an explosion in the number of new companies in synthetic biology and biopharmaceuticals, and large multinational corporations are also increasingly participating in this space," said Will Patrick, CEO and co-founder, Culture Biosciences. “Although demand for biomanufactured products—from food to clothing to vaccines—is surging, there's a huge gap in the infrastructure required to produce these bioproducts at commercial scale.”